PDF(Pubmed)
Abstract：
BACKGROUND: Foot-and-mouth disease (FMD) is a devastating disease affecting cloven-hoofed animals, that leads to significant economic losses in affected countries and regions. Currently, there is an evident inclination towards the utilization of nanoparticles as powerful platforms for innovative vaccine development. Therefore, this study developed a ferritin-based nanoparticle (FNP) vaccine that displays a neutralizing epitope of foot-and-mouth disease virus (FMDV) VP1 (aa 140-158) on the surface of FNP, and evaluated the immunogenicity and protective efficacy of these FNPs in mouse and guinea pig models to provide a strategy for developing potential FMD vaccines.
RESULTS: This study expressed the recombinant proteins Hpf, HPF-NE and HPF-T34E via an E. coli expression system. The results showed that the recombinant proteins Hpf, Hpf-NE and Hpf-T34E could be effectively assembled into nanoparticles. Subsequently, we evaluated the immunogenicity of the Hpf, Hpf-NE and Hpf-T34E proteins in mice, as well as the immunogenicity and protectiveness of the Hpf-T34E protein in guinea pigs. The results of the mouse experiment showed that the immune efficacy in the Hpf-T34E group was greater than the Hpf-NE group. The results from guinea pigs immunized with Hpf-T34E showed that the immune efficacy was largely consistent with the immunogenicity of the FMD inactivated vaccine (IV) and could confer partial protection against FMDV challenge in guinea pigs.
CONCLUSIONS: The Hpf-T34E nanoparticles stand out as a superior choice for a subunit vaccine candidate against FMD, offering effective protection in FMDV-infected model animals. FNP-based vaccines exhibit excellent safety and immunogenicity, thus representing a promising strategy for the continued development of highly efficient and safe FMD vaccines.
RESULTS: This study expressed the recombinant proteins Hpf, HPF-NE and HPF-T34E via an E. coli expression system. The results showed that the recombinant proteins Hpf, Hpf-NE and Hpf-T34E could be effectively assembled into nanoparticles. Subsequently, we evaluated the immunogenicity of the Hpf, Hpf-NE and Hpf-T34E proteins in mice, as well as the immunogenicity and protectiveness of the Hpf-T34E protein in guinea pigs. The results of the mouse experiment showed that the immune efficacy in the Hpf-T34E group was greater than the Hpf-NE group. The results from guinea pigs immunized with Hpf-T34E showed that the immune efficacy was largely consistent with the immunogenicity of the FMD inactivated vaccine (IV) and could confer partial protection against FMDV challenge in guinea pigs.
CONCLUSIONS: The Hpf-T34E nanoparticles stand out as a superior choice for a subunit vaccine candidate against FMD, offering effective protection in FMDV-infected model animals. FNP-based vaccines exhibit excellent safety and immunogenicity, thus representing a promising strategy for the continued development of highly efficient and safe FMD vaccines.
摘要：
背景：口蹄疫（FMD）是一种影响偶蹄动物的破坏性疾病，这导致受影响国家和地区的重大经济损失。目前,有明显倾向于利用纳米粒子作为创新疫苗开发的强大平台。因此,这项研究开发了一种基于铁蛋白的纳米颗粒（FNP）疫苗，该疫苗在FNP表面上显示口蹄疫病毒（FMDV）VP1（aa140-158）的中和表位，并评估了这些FNP在小鼠和豚鼠模型中的免疫原性和保护功效，为开发潜在的FMD疫苗提供了策略。
结果：本研究表达了重组蛋白Hpf，HPF-NE和HPF-T34E通过大肠杆菌表达系统。结果表明,重组蛋白Hpf,Hpf-NE和Hpf-T34E可以有效地组装成纳米颗粒。随后，我们评估了Hpf的免疫原性，小鼠Hpf-NE和Hpf-T34E蛋白，以及Hpf-T34E蛋白在豚鼠中的免疫原性和保护性。小鼠试验成果显示Hpf-T34E组的免疫效力年夜于Hpf-NE组。用Hpf-T34E免疫的豚鼠的结果表明，免疫效力与FMD灭活疫苗（IV）的免疫原性基本一致，并且可以在豚鼠中提供针对FMDV攻击的部分保护。
结论：Hpf-T34E纳米颗粒作为抗口蹄疫亚单位疫苗候选物较好的选择，在FMDV感染的模型动物中提供有效的保护。基于FNP的疫苗表现出优异的安全性和免疫原性，因此代表了继续开发高效和安全的FMD疫苗的有希望的策略。
结果：本研究表达了重组蛋白Hpf，HPF-NE和HPF-T34E通过大肠杆菌表达系统。结果表明,重组蛋白Hpf,Hpf-NE和Hpf-T34E可以有效地组装成纳米颗粒。随后，我们评估了Hpf的免疫原性，小鼠Hpf-NE和Hpf-T34E蛋白，以及Hpf-T34E蛋白在豚鼠中的免疫原性和保护性。小鼠试验成果显示Hpf-T34E组的免疫效力年夜于Hpf-NE组。用Hpf-T34E免疫的豚鼠的结果表明，免疫效力与FMD灭活疫苗（IV）的免疫原性基本一致，并且可以在豚鼠中提供针对FMDV攻击的部分保护。
结论：Hpf-T34E纳米颗粒作为抗口蹄疫亚单位疫苗候选物较好的选择，在FMDV感染的模型动物中提供有效的保护。基于FNP的疫苗表现出优异的安全性和免疫原性，因此代表了继续开发高效和安全的FMD疫苗的有希望的策略。
